TARSUS PHARMACEUTICALS INC (TARS) Stock Price & Overview
NASDAQ:TARS • US87650L1035
Current stock price
The current stock price of TARS is 64.51 USD. Today TARS is down by -2.21%. In the past month the price increased by 0.59%. In the past year, price increased by 29.02%.
TARS Key Statistics
- Market Cap
- 2.746B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.62
- Dividend Yield
- N/A
TARS Stock Performance
TARS Stock Chart
TARS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TARS. When comparing the yearly performance of all stocks, TARS turns out to be only a medium performer in the overall market: it outperformed 61.46% of all stocks.
TARS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TARS. The financial health of TARS is average, but there are quite some concerns on its profitability.
TARS Earnings
On February 23, 2026 TARS reported an EPS of -0.2 and a revenue of 151.67M. The company missed EPS expectations (-106.09% surprise) and beat revenue expectations (2.85% surprise).
TARS Forecast & Estimates
15 analysts have analysed TARS and the average price target is 96.52 USD. This implies a price increase of 49.62% is expected in the next year compared to the current price of 64.51.
For the next year, analysts expect an EPS growth of 62.45% and a revenue growth 55.81% for TARS
TARS Groups
Sector & Classification
TARS Financial Highlights
Over the last trailing twelve months TARS reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 47.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.81% | ||
| ROE | -19.34% | ||
| Debt/Equity | 0.21 |
TARS Ownership
TARS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.83 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.11 | 289.223B | ||
| PFE | PFIZER INC | 9.14 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 120.728B | ||
| ZTS | ZOETIS INC | 16.71 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.443B | ||
| VTRS | VIATRIS INC | 5.91 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.11 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TARS
Company Profile
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 370 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Company Info
IPO: 2020-10-16
TARSUS PHARMACEUTICALS INC
15440 Laguna Canyon Road
Irvine CALIFORNIA 92618 US
CEO: Bobak Azamian
Employees: 370
Phone: 19494099820
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you describe the business of TARSUS PHARMACEUTICALS INC?
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 370 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Can you provide the latest stock price for TARSUS PHARMACEUTICALS INC?
The current stock price of TARS is 64.51 USD. The price decreased by -2.21% in the last trading session.
Does TARS stock pay dividends?
TARS does not pay a dividend.
What is the ChartMill technical and fundamental rating of TARS stock?
TARS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists TARS stock?
TARS stock is listed on the Nasdaq exchange.
What is TARSUS PHARMACEUTICALS INC worth?
TARSUS PHARMACEUTICALS INC (TARS) has a market capitalization of 2.75B USD. This makes TARS a Mid Cap stock.
What is the ownership structure of TARSUS PHARMACEUTICALS INC (TARS)?
You can find the ownership structure of TARSUS PHARMACEUTICALS INC (TARS) on the Ownership tab.